The Ebola outbreak in the eastern Democratic Republic of Congo has become the fastest-growing in history, now complicated by challenges such as unpaid health workers' strikes, community resistance fueled by misinformation, and the ongoing threat of rebel activity.
As of recent reports, the outbreak has resulted in nearly 2,000 confirmed cases and over 700 deaths. The virus, caused by the Bundibugyo Ebola virus, is particularly concerning as there are no approved vaccines for this strain. The spread is suspected to have reached two additional provinces, raising concerns about its reach, especially with suspected cases in Kisangani, a major city.
Ebola is a severe and often fatal disease transmitted through direct contact with bodily fluids like blood, vomit, or semen, and contaminated surfaces. Symptoms typically include fever, vomiting, diarrhea, muscle pain, and bleeding. The outbreak's origins are still under investigation, with experts noting that initial tests may have focused on a more common type of Ebola, potentially delaying recognition.
Community engagement has been hampered by suspicion of outsiders and the spread of false information, with some residents denying the virus's existence. Traditional funeral practices, where loved ones prepare bodies, have also been restricted, leading to local anger. Health centers have faced attacks, and outreach teams are working to counter misinformation and promote prevention measures amidst these difficulties.
The situation is further complicated by the outbreak's presence in Goma, a major humanitarian hub recently seized by rebels. Compounding these external pressures, local Ebola responders have gone on strike, protesting weeks of risky work with little to no pay from the Congolese government. Staff at a treatment center in Ituri province, the outbreak's epicenter, have halted operations, raising concerns that further strikes at other strained facilities could severely impede containment efforts.
These challenges arise as researchers begin a study of two potential experimental treatments. The study involves Gilead Sciences’ remdesivir, an antiviral used for COVID-19 that has shown some promise in lab tests against the Bundibugyo virus, and Mapp Biopharmaceutical’s MBP134, an experimental antibody therapy designed to target Ebola viruses. Patients in the study will be randomly assigned to receive standard care, one of the treatments, both, or neither.
The World Health Organization has cautioned that it could take months and up to 1,000 participants to determine the efficacy of these treatments. The study is currently limited to one treatment center in Ituri province, with plans to expand to other locations once conditions permit. The Associated Press receives financial support for global health and development coverage in Africa from the Gates Foundation.